ASBMR 2021 Rare Bone Disease Highlights from Day One

Episode 1 October 02, 2021 00:20:44
ASBMR 2021 Rare Bone Disease Highlights from Day One
COR2ED Medical Education
ASBMR 2021 Rare Bone Disease Highlights from Day One
/

Show Notes

We have partnered with international experts to provide rare bone disease highlights from ASBMR 2021.

This is the first episode in a series of four podcasts, in this episode Dr Mughal and Dr Javaid discuss their highlights.

Other Episodes

Episode 1

August 02, 2022 00:24:06
Episode Cover

Changing paradigms of haemophilia care in Europe

Changing paradigms of haemophilia care in Europe COR2ED Medical Education: In this podcast, Prof. Cedric Hermans and Prof. Jerzy Windyga discuss their perspectives on the changing paradigms of haemophilia care. They share their past experience and their views on the current situation in Europe, based on results from a recent survey and published in Therapeutic Advances in Hematology. The aim of this survey was to determine whether the paradigms of haemophilia care in Europe have changed with the introduction of novel treatment options. In the podcast, the two experts not only discuss the past and present of haemophilia care, but also share their visions on the future.   Prof. Hermans is the Head of the Division of Haematology at the Cliniques Universitaires of Saint-Luc in Brussels, Belgium. Prof. Windyga is the Head of the Department of Haemostasis Disorders and Internal Medicine at the Institute of Haematology and Transfusion Medicine in Warsaw, Poland. Both experts are members of HEMOSTASIS CONNECT’s European Collaborative Haemophilia Network. ...

Listen

Episode 1

November 30, 2021 00:20:49
Episode Cover

The role of VEGFR-TKIs in the treatment of advanced RCC alone or in combination

Prof. Thomas Powles, a Medical Oncologist from Barts Cancer Centre in the UK and Prof. Georg Hutterer, a Urologist from the Medical University of Graz, Austria, discuss the role of VEGFR-TKIs in the treatment of advanced renal cell carcinoma (RCC) alone or in combination with immunotherapy. In this podcast, by COR2ED Medical Education, the two experts discuss key trials (CHECKMATE 214, KEYNOTE 426, CHECKMATE 9ER and CLEAR) which have led to recent updates to the ESMO and EAU treatment guidelines for RCC. Combination treatment with either VEGFR targeted therapy plus a PD-1 or CTLA-4 inhibitor in the first-line setting is discussed as well as VEGFR-TKI monotherapy options at the time of disease progression. They also focus on how to manage treatment toxicity whilst trying to optimise treatment outcomes and preserving patients’ quality of life as well as the use of biomarkers and risk stratification models. ...

Listen

Episode 2

February 07, 2022 00:24:43
Episode Cover

PARP inhibitors in prostate cancer: What nurses need to know

COR2ED Medical Education: Pablo Peinado, Research Nurse Coordinator, and Dr. Elena Castro, medical oncologist, who both work at Hospital Universitario Virgen de la Victoria in Malaga in Spain, discuss ‘The potential of PARP inhibitors in prostate cancer: What nurses need to know’.  In this podcast, the experts discuss PARP inhibitors (PARPi’s), how they work and key data from the registration trials for rucaparib and olaparib, TRITON2 and PROfound.  They also discuss how to select PARPi’s for their prostate cancer patients and where they fit in the overall treatment sequence. Pablo provides some insight into communicating with patients, and the types of questions and concerns they often have in relation to genetic testing and treatment with PARPi’s.  In addition, they also discuss the PARPi’s currently in late-stage development such as niraparib and talazoparib as well as the potential future use of PARPi’s in combination with immunotherapies or androgen receptor pathway inhibitors. ...

Listen